The nocturnal increase in human cerebrospinal fluid production is inhibited by a beta 1-receptor antagonist. 1994

C Nilsson, and F Ståhlberg, and P Gideon, and C Thomsen, and O Henriksen
Department of Medical Cell Research, University of Lund, Sweden.

A circadian variation in human cerebrospinal fluid (CSF) production has recently been demonstrated using magnetic resonance phase imaging. A nightly peak in CSF production was found at approximately 0200, when production is approximately twice the daytime values. In the present study, we have investigated the effect of a beta 1-receptor antagonist, atenolol, on the production of CSF, specifically the nocturnal production peak. CSF production was measured in fourteen healthy volunteers of both sexes in the time interval 1500-1800, with or without drug administration (100 mg orally) at 1800, and a second measurement was made in the time interval 2300-0200. In the absence of drug administration, all nine volunteers showed a significant increase in CSF production at night, from 0.34 +/- 0.06 ml/min in the time interval 1500-1800 to 0.61 +/- 0.05 (SE) ml/min (P < 0.005), confirming the presence of a circadian variation in these individuals. One week later, the experiment was repeated in five of these volunteers, plus an additional five volunteers, but with the administration of 100 mg atenolol orally immediately after the first measurement (at 1800). In five of the volunteers a decrease in CSF production was seen at midnight compared with daytime production values; in two volunteers CSF production remained unchanged, while three volunteers showed increased production. The average CSF production was 32% lower at night (0.27 +/- 0.10 ml/min) compared with the afternoon (0.40 +/- 0.07 ml/min), after administration of atenolol (P = 0.37).(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008279 Magnetic Resonance Imaging Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques. Chemical Shift Imaging,MR Tomography,MRI Scans,MRI, Functional,Magnetic Resonance Image,Magnetic Resonance Imaging, Functional,Magnetization Transfer Contrast Imaging,NMR Imaging,NMR Tomography,Tomography, NMR,Tomography, Proton Spin,fMRI,Functional Magnetic Resonance Imaging,Imaging, Chemical Shift,Proton Spin Tomography,Spin Echo Imaging,Steady-State Free Precession MRI,Tomography, MR,Zeugmatography,Chemical Shift Imagings,Echo Imaging, Spin,Echo Imagings, Spin,Functional MRI,Functional MRIs,Image, Magnetic Resonance,Imaging, Magnetic Resonance,Imaging, NMR,Imaging, Spin Echo,Imagings, Chemical Shift,Imagings, Spin Echo,MRI Scan,MRIs, Functional,Magnetic Resonance Images,Resonance Image, Magnetic,Scan, MRI,Scans, MRI,Shift Imaging, Chemical,Shift Imagings, Chemical,Spin Echo Imagings,Steady State Free Precession MRI
D008297 Male Males
D011943 Receptors, Adrenergic, beta One of two major pharmacologically defined classes of adrenergic receptors. The beta adrenergic receptors play an important role in regulating CARDIAC MUSCLE contraction, SMOOTH MUSCLE relaxation, and GLYCOGENOLYSIS. Adrenergic beta-Receptor,Adrenergic beta-Receptors,Receptors, beta-Adrenergic,beta Adrenergic Receptor,beta-Adrenergic Receptor,beta-Adrenergic Receptors,Receptor, Adrenergic, beta,Adrenergic Receptor, beta,Adrenergic beta Receptor,Adrenergic beta Receptors,Receptor, beta Adrenergic,Receptor, beta-Adrenergic,Receptors, beta Adrenergic,beta Adrenergic Receptors,beta-Receptor, Adrenergic,beta-Receptors, Adrenergic
D002555 Cerebrospinal Fluid A watery fluid that is continuously produced in the CHOROID PLEXUS and circulates around the surface of the BRAIN; SPINAL CORD; and in the CEREBRAL VENTRICLES. Cerebro Spinal Fluid,Cerebro Spinal Fluids,Cerebrospinal Fluids,Fluid, Cerebro Spinal,Fluid, Cerebrospinal,Fluids, Cerebro Spinal,Fluids, Cerebrospinal,Spinal Fluid, Cerebro,Spinal Fluids, Cerebro
D002940 Circadian Rhythm The regular recurrence, in cycles of about 24 hours, of biological processes or activities, such as sensitivity to drugs or environmental and physiological stimuli. Diurnal Rhythm,Nyctohemeral Rhythm,Twenty-Four Hour Rhythm,Nycthemeral Rhythm,Circadian Rhythms,Diurnal Rhythms,Nycthemeral Rhythms,Nyctohemeral Rhythms,Rhythm, Circadian,Rhythm, Diurnal,Rhythm, Nycthemeral,Rhythm, Nyctohemeral,Rhythm, Twenty-Four Hour,Rhythms, Circadian,Rhythms, Diurnal,Rhythms, Nycthemeral,Rhythms, Nyctohemeral,Rhythms, Twenty-Four Hour,Twenty Four Hour Rhythm,Twenty-Four Hour Rhythms
D005260 Female Females
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000319 Adrenergic beta-Antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. Adrenergic beta-Antagonist,Adrenergic beta-Receptor Blockader,Adrenergic beta-Receptor Blockaders,beta-Adrenergic Antagonist,beta-Adrenergic Blocker,beta-Adrenergic Blocking Agent,beta-Adrenergic Blocking Agents,beta-Adrenergic Receptor Blockader,beta-Adrenergic Receptor Blockaders,beta-Adrenoceptor Antagonist,beta-Blockers, Adrenergic,beta-Adrenergic Antagonists,beta-Adrenergic Blockers,beta-Adrenoceptor Antagonists,Adrenergic beta Antagonist,Adrenergic beta Antagonists,Adrenergic beta Receptor Blockader,Adrenergic beta Receptor Blockaders,Adrenergic beta-Blockers,Agent, beta-Adrenergic Blocking,Agents, beta-Adrenergic Blocking,Antagonist, beta-Adrenergic,Antagonist, beta-Adrenoceptor,Antagonists, beta-Adrenergic,Antagonists, beta-Adrenoceptor,Blockader, Adrenergic beta-Receptor,Blockader, beta-Adrenergic Receptor,Blockaders, Adrenergic beta-Receptor,Blockaders, beta-Adrenergic Receptor,Blocker, beta-Adrenergic,Blockers, beta-Adrenergic,Blocking Agent, beta-Adrenergic,Blocking Agents, beta-Adrenergic,Receptor Blockader, beta-Adrenergic,Receptor Blockaders, beta-Adrenergic,beta Adrenergic Antagonist,beta Adrenergic Antagonists,beta Adrenergic Blocker,beta Adrenergic Blockers,beta Adrenergic Blocking Agent,beta Adrenergic Blocking Agents,beta Adrenergic Receptor Blockader,beta Adrenergic Receptor Blockaders,beta Adrenoceptor Antagonist,beta Adrenoceptor Antagonists,beta Blockers, Adrenergic,beta-Antagonist, Adrenergic,beta-Antagonists, Adrenergic,beta-Receptor Blockader, Adrenergic,beta-Receptor Blockaders, Adrenergic
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

C Nilsson, and F Ståhlberg, and P Gideon, and C Thomsen, and O Henriksen
May 1998, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology,
C Nilsson, and F Ståhlberg, and P Gideon, and C Thomsen, and O Henriksen
January 1992, The Journal of investigative dermatology,
C Nilsson, and F Ståhlberg, and P Gideon, and C Thomsen, and O Henriksen
May 1994, Veterinary immunology and immunopathology,
C Nilsson, and F Ståhlberg, and P Gideon, and C Thomsen, and O Henriksen
September 1991, Journal of immunology (Baltimore, Md. : 1950),
C Nilsson, and F Ståhlberg, and P Gideon, and C Thomsen, and O Henriksen
September 1993, The American journal of pathology,
C Nilsson, and F Ståhlberg, and P Gideon, and C Thomsen, and O Henriksen
October 1998, Annals of the rheumatic diseases,
C Nilsson, and F Ståhlberg, and P Gideon, and C Thomsen, and O Henriksen
January 2002, Arthritis research,
C Nilsson, and F Ståhlberg, and P Gideon, and C Thomsen, and O Henriksen
June 2023, Fluids and barriers of the CNS,
C Nilsson, and F Ståhlberg, and P Gideon, and C Thomsen, and O Henriksen
September 1991, Blood,
C Nilsson, and F Ståhlberg, and P Gideon, and C Thomsen, and O Henriksen
January 2015, PloS one,
Copied contents to your clipboard!